Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren, Yulan; Shi, Tingyan; Jiang, Rong; Yin, Sheng; Wang, Pan; Zang, Rongyu.
Int J Gynecol Cancer
; 25(8): 1398-404, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26222486
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension.
Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma.
Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.